Thromb Haemost 2013; 110(02): 390-392
DOI: 10.1160/TH12-12-0896
Letters to the Editor
Schattauer GmbH

Lipid profile is associated with risk of thrombotic complications

Aránzazu García-Raso
1   Division of Hemostasis and Thrombosis, Department of Hematology, University Hospital Fundación Jiménez Díaz, Madrid, Spain
,
Gabriela Simona Ene
1   Division of Hemostasis and Thrombosis, Department of Hematology, University Hospital Fundación Jiménez Díaz, Madrid, Spain
,
Pilar Llamas Sillero
1   Division of Hemostasis and Thrombosis, Department of Hematology, University Hospital Fundación Jiménez Díaz, Madrid, Spain
› Author Affiliations
Further Information

Publication History

Received: 07 December 2012

Accepted after major revision: 06 May 2013

Publication Date:
04 December 2017 (online)

 

 
  • References

  • 1 Cohen AT, Agnelli G, Anderson FA. VTE Impact Assessment Group in Europe (VITAE). et a Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
  • 2 Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107 (Suppl. 01) I22-30.
  • 3 Prandoni P, Lensing AW, Cogo A. et al. The longterm clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
  • 4 Kahn SR, Shrier I, Julian JA. et al. Determinants and time course of the post-thrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008; 149: 698-707.
  • 5 Rosenson RS, Lowe GD. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 1998; 140: 271-280.
  • 6 Doggen CJ, Smith NL, Lemaitre RN. et al. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 1970-1975.
  • 7 van Schouwenburg IM, Mahmoodi BK, Gansevoort RT. et al. Lipid levels do not influence the risk of venous thromboembolism. Results of a population-based cohort study. Thromb Haemost 2012; 108: 923-929.
  • 8 Griffin JH, Fernández JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost 2001; 86: 386-394.
  • 9 Mineo C, Deguchi H, Griffin JH. et al. Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98: 1352-1364.
  • 10 Griffin JH, Kojima K, Banka CL. et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999; 103: 219-227.
  • 11 Yusuf S, Hawken S, Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
  • 12 Deguchi H, Pecheniuk NM, Elias DJ. et al. Highdensity lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005; 112: 893-899.
  • 13 Eichinger S, Pecheniuk NM, Hron G. et al. Highdensity lipoprotein and the risk of recurrent venous thromboembolism. Circulation 2007; 115: 1609-1614.
  • 14 Chamberlain AM, Folsom AR, Heckbert SR. et al. High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood 2008; 112: 2675-2680.
  • 15 Quist-Paulsen P, Naess IA, Cannegieter SC. et al. Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica 2010; 95: 119-125.
  • 16 Ray JG, Rosendaal FR. The role of dyslipidemia and statins in venous thromboembolism. Curr Control Trials Cardiovasc Med 2001; 02: 165-170.
  • 17 Brighton TA, Eikelboom JW, Mann K. et al. the ASPIRE Investigators. Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism. N Engl J Med. 2012 Epub ahead of print..
  • 18 Eichinger S, Pecheniuk NM, Hron G. et al. Highdensity lipoprotein and the risk of recurrent venous thromboembolism. Circulation 2007; 115: 1609-1614.